<prompt> EGFR antagonist, Cetuximab is used in cases ofPalliative treatment of head and neck cancerAnal canal carcinomaGastric carcinomaSmall cell lung carcinoma  <response>: Cetuximab and pemtumomab are directed against the epidermal growth factor receptor EGFR, a transmembrane glycoprotein involved in signaling pathways affecting growth and proliferation of tumor cells. Both cetuximab and pemtumomab, when given alone, have been shown to benefit a small propoion of previously treated patients 